TG Therapeutics (TGTX)
(Delayed Data from NSDQ)
$24.65 USD
-0.63 (-2.49%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $24.64 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
TG Therapeutics, Inc. [TGTX]
Reports for Purchase
Showing records 61 - 80 ( 278 total )
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Positive Top-Line Results for Ubilituximab in Phase 3 Ultimate I and II Trials in MS; Raising PT to $61
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
U2 and Venclexta Combination Data Impress at ASH 2020
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Company: TG Therapeutics, Inc.
Industry: Medical - Products
3Q20 Results; Numerous ASH Abstracts Last Week; Looking to Umbralisib Approvals in 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Highlights From ASH Abstracts; Potential for Five FDA Approvals in 2021-2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Company: TG Therapeutics, Inc.
Industry: Medical - Products
FDA Grants Fast Track Designation to Ublituximab in Combination With Umbralisib in Adult Patients With CLL
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Company: TG Therapeutics, Inc.
Industry: Medical - Products
2Q20 Results; All Eyes on Upcoming MZL and FL PDUFA Date and Approval; Raising PT to $38
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Rolling NDA Submission Completed for Umbralisib in MZL and FL
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Company: TG Therapeutics, Inc.
Industry: Medical - Products
TG Therapeutics Stock Offering; ASCO and EHA Abstract Update Positive Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
1Q20 Results; Two FDA Submissions for Three Indications in 2020; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Interim Analysis for UNITY-CLL Yields Positive Results
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
FDA Grants Orphan Drug Designation for Umbralisib in FL
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
4Q19 Results; Interim UNITY-CLL Data Expected Within 90 Days
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Rolling NDA Submission for Umbralisib in MZL and FL; Raising PT by $4 to $24
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Good BTK Data, Coupled With Strong Triple Combo Data in CLL Make for a Positive Investor Event at ASH
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E